Issue 7/2023
Pehlivanov, G., Argirov, A.
MBAL VITA 2 – Sofia
Psoriasis is one of the most common skin diseases. It affects 2 to 3% of Europeans. In Bulgaria, nearly 140,000 people live with psoriasis. It has a genetic origin and affects men and women equally. Today, there is a growing understanding that psoriasis is more than a chronic skin disease and that it is a systemic inflammatory disease. Historically, numerous topical medications, systemic oral and parenteral therapy, phototherapy and thalassotherapy have been used to treat psoriasis patients. None of these therapeutic methods have given a lasting satisfactory result. A qualitatively new stage in the therapy not only of psoriasis, but also of other chronic severe diseases, are biological agents. Biologics are molecules that block specific stages of the inflammatory cascade in psoriasis by attacking either immune T-cells (Th1, Th17) or pro-inflammatory cytokines (TNF-α, Il-17,22, IFN-γ, AMPs).
Key words: psoriasis, treatment of psoriasis, biological agents
Address for correspondence:
Markova, R.
First Pediatric Consultative Clinic – Sofia
1404, Sofia
51 “Bulgaria”, Blvd.